Researchers in the King lab, an affiliate of the Institute for Protein Design, published a report in Cell describing a computer-designed nanoparticle vaccine targeting respiratory syncytial virus (RSV). Although Rosetta@home was not directly used for this study, Rosetta@home volunteers provided computing for related research and development.

From IPD news:

Millions of children will visit hospitals this year, sickened by RSV. Infection is usually mild, causing only fevers, runny noses and frightened parents. But, in severe cases, barking coughs and painful wheezing can indicate serious respiratory complications, including bronchiolitis and pneumonia.

RSV is the primary cause of pneumonia in children under one and is therefore the leading cause of infant mortality worldwide after malaria. Although virtually every child on Earth will get RSV before the age of three, an estimated 99 percent of RSV deaths occur in developing countries. Despite substantial effort, there is not yet a safe and effective vaccine.

Today, an international team of scientists co-led by researchers at the IPD report in Cell a first-of-its-kind vaccine candidate for RSV. It elicits broadly neutralizing antibodies against respiratory syncytial virus in mice and monkeys, paving the way for human clinical trials.

---

Per the IPD's annual report, this vaccine candidate is planned to enter into a Phase 1 clinical trial in April 2021.

"The IPD has transferred methods for producing and characterizing it to the NIH, where it is currently being manufactured for planned entry into a Phase I clinical trial in April 2021"

Page 7.

---

Correct version of my comment:

This vaccine is planned to begin a Phase 1 clinical trial in the first quarter of 2021.
See page 6 of the Annual IPD report

---

Great post, very informative! Thanks for sharing.
https://www.curatedleads.org/flooring-leads